Tag: Forty Seven

Gilead Sciences wraps up $4.9bn acquisition of Forty Seven

pharmanewsdaily- April 13, 2020

Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been ... Read More

Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

pharmanewsdaily- March 3, 2020

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More